The association between lesion tracer uptake on 68Ga-DOTATATE PET with morphological response to 177Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors

Nucl Med Commun. 2022 Jan 1;43(1):73-77. doi: 10.1097/MNM.0000000000001488. ABSTRACT PURPOSE: To determine in a group of patients with progressive metastatic neuroendocrine tumors (PM-NETs) treated with 177Lu-DOTATATE whether a correlation exists between somatostatin receptor (SSTR)-2 expression in various tumors on baseline…

18F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center

Curr Oncol. 2021 Aug 25;28(5):3251-3258. doi: 10.3390/curroncol28050282. ABSTRACT PURPOSE: To describe the initial experience of an academic center using 18F-DCFPyL PET in managing men with recurrent prostate cancer. MATERIALS & METHODS: This prospective, single-arm IRB-approved study included men with biochemical…

Neuroendocrine Tumors: Imaging Perspective

PET Clin. 2021 Jul;16(3):353-364. doi: 10.1016/j.cpet.2021.03.002. ABSTRACT This article summarizes the role of PET imaging for detection, characterization, and theranostic/therapy planning for neuroendocrine tumors. Topics in this article span overall imaging accuracy with mostly 68Ga-DOTA-peptide imaging as well as basic…

Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR

Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3702-3711. doi: 10.1007/s00259-021-05355-7. Epub 2021 Apr 12. ABSTRACT PURPOSE: To assess whether 18F-DCFPyL PET/multiparametric (mp)MR contributes to the diagnosis of clinically significant (cs) prostate cancer (PCa) compared to mpMR in patients with suspicion…